ClinicalTrials.gg
RecruitingNCT07359534THRIVEUpdated Jan 22, 2026

Training Health Recovery and Improvement Via Levagen+® Evaluation

An interventional study of Levagen+® Palmitoylethanolamide (PEA) and Placebo in Exercise Recovery, sponsored by University of Westminster. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Primary conditionInflammation(the registry's first term)UnverifiedIs this wrong?Inflammation is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by University of Westminster · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Mar 2025, registered Jan 2026).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

INTRODUCTION:

Sports supplements and ergogenic aids are widely used for performance enhancement in recreational and professional sports. Athletes undergo intense training to improve their cardiorespiratory and muscular systems, aiming for positive adaptations. However, intensified training without appropriate dietary support can pose risks such as inadequate muscle recovery, weakened immune function, and reduced sleep quality, leading to increased susceptibility to illness and heightened physiological and psychological stress. The recent removal of cannabidiol (CBD) from the World Anti-Doping Agency (WADA) prohibited list has increased its popularity among athletes for its potential benefits on recovery and sleep. However, concerns about its safety and legality in sport persist, leading many governing bodies to caution against its use.

Palmitoylethanolamide (PEA), a Generally Recognised as Safe (GRAS) supplement, exhibits anti-inflammatory effects and supports joint health. It also shows potential for stress and anxiety management, with ongoing research demonstrating this. Levagen+®, a formulated PEA, offers a safe, legal alternative to CBD, showing promise for recovery and sleep improvements. Additionally, PEA demonstrates neuroprotective and immunomodulating properties, indicating the potential benefits for athlete health, performance, and recovery. However, further research is needed to confirm Levagen+®'s efficacy as an ergogenic aid, especially in endurance sports.

The aim of this trial is to explore the effects of Levagen+® supplementation on physical, physiological and psychological recovery during a prolonged period (one week) of intensified cycling training, when administered over a period of 45 days.

Read the detailed description

An intervention study with two treatment groups in a randomised, double-blind, crossover design.

Study population: Healthy, trained endurance cyclists (male or female) will receive supplements (active PEA or equivalent placebos allocated randomly) daily for 45 days, followed by a minimum 4-week washout period before receiving the other intervention.

Participants will be required to complete a cycling performance test (Functional Threshold Power [FTP] test) at home the day before attending laboratory testing visits 1, 2 and 4 (Day 0, Day 35 and Day 45 of supplementation), respectively. On the baseline first visit (Day 0), second (Day 35), third (Day 43) and endpoint fourth visits (Day 45) to the research facility, participants will be requested to complete an endurance cycling test (a 40 km time trial). Blood samples and pertinent questionnaires (Visual Analogue Scale (VAS) assessing muscle soreness; questionnaires assessing perception of exertion and arousal; sleep quality, mood and oral supplementation questionnaires) will also be collected at the aforementioned time points.

Participants will be required to follow and record their regular training regime from Day 1 to Day 35 of the study. The collected data over the course of these 5 weeks will be used to establish the intensified training protocol, whereby the average training load of the participant will be increased by 50%. The intensified training protocol will be assigned to participants to be completed over a 7-day period between the second visit (Day 35) and the third visit (Day 43). Participants will visit the research facility on Day 43 and Day 45 to assess recovery on day 1 and day 3 post intensified training period.

02

Conditions studied

  • Exercise Recovery

Browse trials for

Keywords

  • nutraceutical
  • exercise recovery
  • sport
  • cycling
  • inflammation
  • muscle recovery
  • sleep quality
  • Palmitoylethanolamide
03

In context

Inflammation Unverified

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

This study's planned enrollment of 20 is below the median of 50 across 2,586 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

University of Westminster is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Compared within Inflammation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects
  • Males and females (18-50 years of age)
  • Trained cyclists/triathletes indicated by:
  • Minimum functional threshold power (FTP, an indication of the highest average power output a cyclist can maintain for 60 minutes) of 2.9W/kg for males and 2.5W/kg for females
  • Minimum 2 years of 5 hours cycling training a week

Exclusion criteria

Exclusion Criteria:

  • \<18, >50 years
  • Following a restrictive diet plan
  • Consumption of >14 units of alcohol/week
  • Allergies to test foods/drinks
  • Illnesses or on medication (with a possible effect on taste and/or appetite)
  • Devices such as pacemakers
  • Smokers
  • Gastrointestinal disorders
  • Eating disorders
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Levagen+® Palmitoylethanolamide (PEA)

    Levagen+® Palmitoylethanolamide (PEA) - 350mg/day, containing not less than 300 mg PEA

    Dietary Supplement: Levagen+® Palmitoylethanolamide (PEA)

  • Placebo comparator
    Placebo

    Placebo - Microcrystalline Cellulose

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementLevagen+® Palmitoylethanolamide (PEA)

    Drug page: PalmidrolStudies of PalmidrolPalmidrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants were instructed to consume 1 opaque capsule (350 mg Levagen+®, not less than 300mg PEA) with water daily at the same time of the day for 45 days.

  • Dietary supplementPlacebo

    Participants were instructed to consume 1 opaque capsule (Microcrystalline Cellulose) with water daily at the same time of the day for 45 days.

06

What researchers measure

Primary outcomes

  1. Exercise performance following intensified training during cycling tests in PEA supplemented athletes

    The duration of completing the 40 km cycling time trial (hh:mm:ss)

    Time frame: The parameters will be measured before the 40km cycling time trial and every 10km during the trial (overall completion time will also be recorded) on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43), endpoint forth visit (Day45)

  2. Exercise performance following intensified training during cycling tests in PEA supplemented athletes

    Perceptions of exertion (RPE: Borg 6-20 scale, where 6 equals no exertion and 20 equals maximal exertion)

    Time frame: The parameters will be measured before the 40km cycling time trial and every 10km during the trial (overall completion time will also be recorded) on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43), endpoint forth visit (Day45)

  3. Changes in levels of fatigue, quality of sleep, muscle soreness and mood during the intensified training and recovery period using questionnaires.

    Hooper and MacKinnon Questionnaire: a subjective assessment of the impact of DOMS in the domains of fatigue, sleep quality, general muscle soreness, stress level, and mood on a scale of 1-7, with higher scores denoting the worst results.

    Time frame: Questionnaires collected daily between days 33 and 45 (inclusive)

  4. Changes in exercise-associated inflammatory markers associated with intensified training in PEA supplemented athletes

    Interleukin-6 (pg/mL)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  5. Changes in exercise-associated inflammatory markers associated with intensified training in PEA supplemented athletes

    Tumour necrosis factor-alpha (pg/mL)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

Secondary outcomes

  1. Changes in exercise-associated oxidative stress markers associated with intensified training in PEA supplemented athletes

    Tbars (µM)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  2. Changes in exercise-associated oxidative stress markers associated with intensified training in PEA supplemented athletes

    F2-Isoprostane (pg/ml)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  3. Changes in stress hormone levels associated with intensified training in PEA supplemented athletes

    Cortisol (nmol/l)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  4. Changes in stress hormone levels associated with intensified training in PEA supplemented athletes

    Testosterone (nmol/L)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  5. Changes in neurotrophic factor levels in PEA supplemented athletes

    Brain-Derived Neurotrophic Factor (pg/ml)

    Time frame: The parameters will be measured before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  6. Perceptions of muscle pain associated with intensified training in PEA supplemented athletes

    Visual Analogue Scale; scores range from 0 to 100 (the higher the score the greater the level of perceived pain)

    Time frame: The parameters will be measured immediately before and immediately after exercise on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  7. Changes in state and profile of perceived mood during intensified training and recovery phase using questionnaires.

    Profile of Mood States (POMS) Questionnaire: a psychological assessment comprising forty questions. The forty items yield scores on six factors: Tension, Depression (depressed mood), Anger, Vigour, Fatigue, and Confusion. The responses are evaluated on five-point response scales ranging from 0 to 4, where 0 represents the 'lack of' and 4 represents the 'most extreme' experience of a particular feeling.

    Time frame: Questionnaires collected daily between days 33 and 45 (inclusive)

  8. Perceptions of exercise-associated pleasure during endurance cycling (40km time trial) in PEA supplemented athletes

    Felt Arousal Scale: a 6-point Likert scale measuring arousal from 1 ("low arousal" to 6 ("high arousal").

    Time frame: Perceived pleasure will be assessed immediately before the 40km time trial and every 10km during the trial, on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43) and endpoint forth visit (Day 45)

  9. Incidence and frequency of Levagen+® associated-gastrointestinal symptoms

    Subjective analysis using the Gastrointestinal Symptoms Rating Scale (GSRS, on a 1 to 7 Likert scale, where 1 = no discomfort, 7 = very severe discomfort).

    Time frame: gastrointestinal symptoms analysed daily during the supplementation period between days 33 and 45 (inclusive)

  10. Metabolic changes following intensified training during cycling tests in PEA supplemented athletes

    Blood glucose concentration (mmol/L)

    Time frame: The parameters will be measured before the 40km cycling time trial and every 10km during the trial (overall completion time will also be recorded) on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43), endpoint forth visit (Day 45)

  11. Metabolic changes following intensified training during cycling tests in PEA supplemented athletes

    Blood lactate concentration (mmol/L)

    Time frame: The parameters will be measured before the 40km cycling time trial and every 10km during the trial (overall completion time will also be recorded) on baseline first visit (Day 0), second visit (Day 35), third visit (Day 43), endpoint forth visit (Day 45)

07

Study locations

1 of 1 sites recruiting
  • University of Westminster London
    London, W1W 6UW, United Kingdom
    Recruiting
    • Helena Tiekou Lorinczova, PhD · Contacth.tiekoulorinczova1@westminster.ac.uk
    • Mohammed Gulrez Zariwala, PhD · Principal investigator
    • Vinood B Patel, PhD · Sub investigator
    • Gulshanara (Rumy) Begum, PhD · Sub investigator
    • Helena Tiekou Lorinczova, PhD · Sub investigator
    • Victoria G Linsley, PhD · Sub investigator
    • Sanjoy Deb, PhD · Sub investigator
    • Marta M Gámez-Fernández, PhD · Sub investigator
08

References and documents

Publications

  • Nerys Williams, The Borg Rating of Perceived Exertion (RPE) scale, Occupational Medicine, Volume 67, Issue 5, July 2017, Pages 404-405, https://doi.org/10.1093/occmed/kqx063
  • J Wadley A, S Svendsen I, Gleeson M. Heightened Exercise-Induced Oxidative Stress at Simulated Moderate Level Altitude vs. Sea Level in Trained Cyclists. Int J Sport Nutr Exerc Metab. 2017 Apr;27(2):97-104. doi: 10.1123/ijsnem.2015-0345. Epub 2016 Oct 6. PubMed 27710149 ↗
  • Mallard A, Briskey D, Richards A, Mills D, Rao A. The Effect of Orally Dosed Levagen+ (palmitoylethanolamide) on Exercise Recovery in Healthy Males-A Double-Blind, Randomized, Placebo-Controlled Study. Nutrients. 2020 Feb 25;12(3):596. doi: 10.3390/nu12030596. PubMed 32106527 ↗
  • LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci. 2005 Aug 19;77(14):1685-98. doi: 10.1016/j.lfs.2005.05.012. PubMed 15963531 ↗
  • Konopka AR, Harber MP. Skeletal muscle hypertrophy after aerobic exercise training. Exerc Sport Sci Rev. 2014 Apr;42(2):53-61. doi: 10.1249/JES.0000000000000007. PubMed 24508740 ↗
  • Kim N, Parolin B, Renshaw D, Deb SK, Zariwala MG. Formulated Palmitoylethanolamide Supplementation Improves Parameters of Cognitive Function and BDNF Levels in Young, Healthy Adults: A Randomised Cross-Over Trial. Nutrients. 2024 Feb 8;16(4):489. doi: 10.3390/nu16040489. PubMed 38398813 ↗
  • Killer SC, Svendsen IS, Jeukendrup AE, Gleeson M. Evidence of disturbed sleep and mood state in well-trained athletes during short-term intensified training with and without a high carbohydrate nutritional intervention. J Sports Sci. 2017 Jul;35(14):1402-1410. doi: 10.1080/02640414.2015.1085589. Epub 2015 Sep 25. PubMed 26406911 ↗
  • Kasper AM, Sparks SA, Hooks M, Skeer M, Webb B, Nia H, Morton JP, Close GL. High Prevalence of Cannabidiol Use Within Male Professional Rugby Union and League Players: A Quest for Pain Relief and Enhanced Recovery. Int J Sport Nutr Exerc Metab. 2020 Sep 1;30(5):315-322. doi: 10.1123/ijsnem.2020-0151. Epub 2020 Jul 30. PubMed 32732454 ↗
  • Keppel Hesselink JM, de Boer T, Witkamp RF. Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold. Int J Inflam. 2013;2013:151028. doi: 10.1155/2013/151028. Epub 2013 Aug 27. PubMed 24066256 ↗
  • Hellsten Y, Nyberg M. Cardiovascular Adaptations to Exercise Training. Compr Physiol. 2015 Dec 15;6(1):1-32. doi: 10.1002/cphy.c140080. PubMed 26756625 ↗
  • Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111/bcp.13020. Epub 2016 Jun 29. PubMed 27220803 ↗
  • Evangelista M, Cilli, De Vitis R, Militerno A, Fanfani F. Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study. CNS Neurol Disord Drug Targets. 2018;17(4):291-298. doi: 10.2174/1871527317666180420143830. PubMed 29676237 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 12 months is below that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 22, 2026
StartActual
Mar 10, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Apr 30, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359534
Lead sponsor
University of Westminster
Collaborators
Anglia Ruskin University
Responsible party
Mohammed Gulrez Zariwala (Professor of Translational Physiology, University of Westminster) — Principal investigator
First posted
Jan 22, 2026
Start date
Mar 10, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Mohammed Gulrez Zariwala, PhD
Contact
m.zariwala@westminster.ac.uk
0044 (0)20 7911 5000 ext. 65086
Helena Tiekou Lorinczova, PhD
Contact
h.tiekoulorinczova1@westminster.ac.uk
Mohammed Gulrez Zariwala, PhD
principal investigator · University of Westminster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palmidrol

Start the discussion